Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Micro non-coding RNA antagonist and use thereof

A non-coding, antagonistic technology, applied in the field of mental and nervous system diseases, can solve the problem of unclear molecular regulation mechanism, achieve the effect of inhibiting the release process and promoting the occurrence

Active Publication Date: 2019-01-18
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the molecular regulatory mechanism exists is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Micro non-coding RNA antagonist and use thereof
  • Micro non-coding RNA antagonist and use thereof
  • Micro non-coding RNA antagonist and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: lenti-AMO-miR-153-3p can be used to improve neurotransmitter release disorders induced by long-term cerebral hypoperfusion

[0053] 1. Construction of long-term cerebral hypoperfusion rat model

[0054] 1. The CBH model constructed by permanent ligation of bilateral common carotid arteries (2VO) can effectively simulate the preclinical cerebral blood flow state of AD patients, and is considered to be a classic animal model for studying long-term cerebral hypoperfusion.

[0055] 2. Model construction method: Male SD rats were fasted for 12 hours before operation, and were anesthetized by intraperitoneal injection of 10% chloral hydrate (300 mg / kg). Monitor the rat's heart rate and respiratory rate during surgery to avoid death of the animal due to too deep anesthesia. Rats were fixed on the operating board in the supine position, and the skin on the neck was prepared and sterilized with 75% alcohol. A median neck incision was made, and the subcutaneous tissu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The invention discloses a micro non-coding RNA antagonist and the use thereof. The micro non-coding RNA antagonist is miR-153-The antisense oligonucleotide (AMO 153 3p) of the 3p seed sequence is shown in SEQ ID NO. 1. Compared with the prior art, the invention has the advantage that a large number of experiments prove that in the long-term cerebral ischemia-hypoxia rat model induced by long-termcerebral hypoperfusion, miR-153-3p is overexpressed in the hippocampal cortex, which can regulate the expression of several neurotransmitter-releasing related proteins through multiple targets, and inhibit the release of neurotransmitters, thus promoting the occurrence of cognitive impairment in the brain. Targeted inhibition miR-153-The expression of 3p specifically blocked miR-153-Inhibitory effect of 3p on neurotransmitter release. Therefore, AMO-153-3p can be used for the prevention and treatment of various neurotransmitter release disorders induced by long-term cerebral ischemia and hypoxia.

Description

technical field [0001] The present invention relates to a small non-coding RNA antagonist AMO-153-3p in the treatment of neurotransmitter release disorder induced by long-term cerebral ischemia and hypoxia and the mental and nervous system diseases caused by it, including Alzheimer's disease and vascular disease Applications in dementia. The invention belongs to the technical field of biomedicine. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease closely related to age and characterized by progressive cognitive impairment, and it is the most important type of senile dementia. Its clinical symptoms are mainly manifested as progressive memory decline, cognitive dysfunction and neuropsychiatric abnormalities, and eventually behavioral changes. There are more than 40 million Alzheimer's patients in the world. Due to the aging of the global population and the lack of effective treatments, the number of patients is expected to triple by 2050. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7088A61P25/00A61P25/28
CPCA61P25/00A61P25/28A61K31/7088
Inventor 艾静闫美玲张帅孙丽华
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com